1. pregnant or breast feeding 2. clinically significant abnormalities in medical history 3. out of range screening laboratory results 4. known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b 5. uncontrolled hypertension (bp \> 160/100 mm hg) 6. uncontrolled diabetes 7. any history of autoimmune disease 8. immunodeficiency of any cause 9. history of chronic liver disease 10. treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer 11. recent (within 1 year) history of, or current drug or alcohol abuse 12. has any blood dyscrasias or significant disorder of coagulation 13. has an acute illness, as determined by the investigator, with or without fever \[temperature \>38.0 degrees celsius (100.4 degrees fahrenheit)\] within 72 hours prior to each vaccination 14. malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 15. received or plans to receive another vaccine within 4 weeks before study vaccination or at any time during the study. 16. receipt of any other sars cov-2 or other experimental coronavirus vaccine at any time prior to study or planned during the study 17. have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study

1. pregnant or breast feeding 2. clinically significant abnormalities in medical history 3. out of range screening laboratory results 4. known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b 5. uncontrolled hypertension (bp \> 160/100 mm hg) 6. uncontrolled diabetes 7. any history of autoimmune disease 8. immunodeficiency of any cause 9. history of chronic liver disease 10. treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer 11. recent (within 1 year) history of, or current drug or alcohol abuse 12. has any blood dyscrasias or significant disorder of coagulation 13. has an acute illness, as determined by the investigator, with or without fever \[temperature \>38.0 degrees celsius (100.4 degrees fahrenheit)\] within 72 hours prior to each vaccination 14. malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 15. received or plans to receive another vaccine within 4 weeks before study vaccination or at any time during the study. 16. receipt of any other sars cov-2 or other experimental coronavirus vaccine at any time prior to study or planned during the study 17. have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study

pregnant or breast feeding clinically significant abnormalities in medical history out of range screening laboratory results known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b uncontrolled hypertension (bp > 160/100 mm hg) uncontrolled diabetes any history of autoimmune disease immunodeficiency of any cause history of chronic liver disease treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer recent (within 1 year) history of, or current drug or alcohol abuse has any blood dyscrasias or significant disorder of coagulation has an acute illness, as determined by the investigator, with or without fever [temperature >38.0 degrees celsius (100.4 degrees fahrenheit)] within 72 hours prior to each vaccination malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. received or plans to receive another vaccine within 4 weeks before study vaccination or at any time during the study. receipt of any other sars cov-2 or other experimental coronavirus vaccine at any time prior to study or planned during the study have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study

pregnant or breast feeding clinically significant abnormalities in medical history out of range screening laboratory results known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b uncontrolled hypertension (bp > 160/100 mm hg) uncontrolled diabetes any history of autoimmune disease immunodeficiency of any cause history of chronic liver disease treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer recent (within 1 year) history of, or current drug or alcohol abuse has any blood dyscrasias or significant disorder of coagulation has an acute illness, as determined by the investigator, with or without fever [temperature >38.0 degrees celsius (100.4 degrees fahrenheit)] within 72 hours prior to each vaccination malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. received or plans to receive another vaccine within 4 weeks before study vaccination or at any time during the study. receipt of any other sars cov-2 or other experimental coronavirus vaccine at any time prior to study or planned during the study have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study

1. pregnant or breast feeding 2. clinically significant abnormalities in medical history 3. out of range screening laboratory results 4. known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b 5. uncontrolled hypertension (bp > 160/100 mm hg) 6. uncontrolled diabetes 7. any history of autoimmune disease 8. immunodeficiency of any cause 9. history of chronic liver disease 10. treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer 11. recent (within 1 year) history of, or current drug or alcohol abuse 12. has any blood dyscrasias or significant disorder of coagulation 13. has an acute illness, as determined by the investigator, with or without fever [temperature >38.0 degrees celsius (100.4 degrees fahrenheit)] within 72 hours prior to each vaccination 14. malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 15. received or plans to receive another vaccine within 4 weeks before study vaccination or at any time during the study. 16. receipt of any other sars cov-2 or other experimental coronavirus vaccine at any time prior to study or planned during the study 17. have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study

1. pregnant or breast feeding 2. clinically significant abnormalities in medical history 3. out of range screening laboratory results 4. known history of or positive test for human immunodeficiency virus (hiv), hepatitis c or chronic hepatitis b 5. uncontrolled hypertension (bp > 160/100 mm hg) 6. uncontrolled diabetes 7. any history of autoimmune disease 8. immunodeficiency of any cause 9. history of chronic liver disease 10. treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer 11. recent (within 1 year) history of, or current drug or alcohol abuse 12. has any blood dyscrasias or significant disorder of coagulation 13. has an acute illness, as determined by the investigator, with or without fever [temperature >38.0 degrees celsius (100.4 degrees fahrenheit)] within 72 hours prior to each vaccination 14. malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 15. received or plans to receive another vaccine within 4 weeks before study vaccination or at any time during the study. 16. receipt of any other sars cov-2 or other experimental coronavirus vaccine at any time prior to study or planned during the study 17. have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study